Five patients in England with severe lupus have achieved remission following treatment with CAR T-cell therapy, a technique that genetically modifies a patient’s own immune cells to combat disease. According to researchers at University College London (UCL) and University College London Hospitals (UCLH), the therapy resets the immune system, potentially offering a long-term cure for a condition that previously required lifelong medication.
How does CAR T-cell therapy work for lupus?
CAR T-cell therapy functions by harvesting a patient’s T lymphocytes—white blood cells responsible for immune defense—and engineering them to recognize and destroy specific disease-causing cells. Once modified, these cells are infused back into the patient. According to UCLH, this process effectively “resets” the immune system. While the therapy is established in oncology, this marks a successful application for severe autoimmune conditions, specifically targeting lupus patients who had previously failed to respond to standard treatments.
Lupus affects approximately 5 million people worldwide. The disease causes the immune system to attack healthy tissue, leading to chronic inflammation that can damage the heart, lungs, and kidneys.
What were the results of the NHS clinical trial?
In a trial involving nine patients, five individuals who received a lower dose of the therapy entered remission within months. According to data from the UCL/UCLH study, these participants showed rapid stabilization of kidney function—a critical marker, as many suffered from lupus nephritis. Three additional patients who received a higher dose are currently being monitored, with researchers expressing optimism that they will follow a similar path to recovery.
How does this compare to traditional lupus treatments?
Traditional lupus management relies on chronic immunosuppressants designed to manage symptoms and prevent organ damage, often for the duration of a patient’s life. In contrast, CAR T-cell therapy is a one-time infusion. Katie Tinkler, a 52-year-old patient who struggled with systemic organ failure and joint pain for decades, reports that her life is “unrecognisable” since the treatment. She has regained the ability to participate in physical activities, such as skiing, which were previously impossible due to her condition.
What are the future implications for autoimmune research?
Prof. Karl Peggs, director of the UCLH biomedical research centre, states that while larger-scale studies are required to confirm these findings, the results represent a shift in how clinicians might treat chronic autoimmune diseases. By moving from symptom management to a curative “immune reset,” the medical community may eventually eliminate the need for long-term pharmaceutical intervention in lupus cases. Future research will focus on whether these remission periods remain durable over several years.
Frequently Asked Questions
Is CAR T-cell therapy a permanent cure for lupus?
Early results are promising, with five patients in remission. However, doctors at UCLH note that larger studies are needed to confirm the long-term efficacy of the treatment.
Who is eligible for this therapy?
The current trial focused on patients with severe, treatment-resistant lupus, including those with kidney complications.
What are the main symptoms of lupus?
Symptoms vary but often include severe fatigue, joint pain, skin rashes, and inflammation of vital organs like the heart and kidneys.
If you or a loved one are living with a chronic autoimmune condition, consult with a specialist about clinical trials. You can search for ongoing research through the National Institutes of Health or local university hospital registries.
Have you or a family member been affected by autoimmune disease? Share your thoughts in the comments below or subscribe to our health briefing for the latest updates on medical breakthroughs.
Worth a look